Use of Semaphorin 6A for Promoting Myelination and Oligodendrocyte Differentiation

A technology of oligodendrocytes and myelin sheaths, applied in the fields of neurology, pharmacology, and neurobiology, which can solve problems such as poorly understood functions

Inactive Publication Date: 2010-01-20
BIOGEN MA INC +2
View PDF30 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Many transmembrane semaphorins are expressed in the developing CNS, but their functions in vivo are poorly understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Semaphorin 6A for Promoting Myelination and Oligodendrocyte Differentiation
  • Use of Semaphorin 6A for Promoting Myelination and Oligodendrocyte Differentiation
  • Use of Semaphorin 6A for Promoting Myelination and Oligodendrocyte Differentiation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0213] Sema6A is involved in the biology of oligodendrocytes

[0214]Oligodendrocyte maturation goes through several developmental stages, from oligodendrocyte progenitor cells (which express NG2) to pre-myelinating oligodendrocytes (which express O1 and O4 ) and eventually differentiate into mature myelinating oligodendrocytes (which express O1, O4, myelin basic protein (MBP) and anti-proteolipid protein (PLP)). Thus, by monitoring the presence or absence of NG2, O1, O4, MBP and PLP markers, it is possible to determine the developmental stage of a given cell and evaluate the role of Sema6A polypeptides in oligodendrocyte biology. Oligodendrocyte transcription factor-2 (Olig-2) is also thought to be expressed in the oligodendrocyte lineage and is therefore used as a marker to detect oligodendrocytes. See Yokoo et al., Amer. J. of Path. 164:1717-1725 (2004) (for a review of oligodendrocyte biology see, eg, Baumann and Pham-Dinh, Physiol. Rev. 81:871-927 (2001) ; Bras et al., ...

Embodiment 2

[0225] Expression of Sema6A in different stages of oligodendrocyte differentiation

[0226] In vitro Sema6A expression was also shown in purified oligodendrocyte cultures. The cortical hemispheres of P0 to P5 mice were excised and transferred to a medium consisting of DMEM supplemented with 10% calf serum. In culture medium, the tissue was separated by passing through a 70 μm mesh nylon mesh. The cell suspension was dispensed onto 100 mm diameter plastic tissue culture dishes coated with polyornithine. Oligodendrocyte precursor cells were selectively isolated by gently syringeing the medium above the cell layer. The removed cells were then subjected to two consecutive preplatings on uncoated plastic dishes over a 12 hour period to allow the remaining astrocytes and microglia to attach. Non-attached as well as loosely attached cells (oligodendrocytes) were subcultured on 60mm plastic dishes. Anti-mouse Sema6A antibody and anti-NG2 (marker of oligodendrocyte progenitor cells...

Embodiment 3

[0228] Sema6A-knockout mice exhibit reduced myelinated axons

[0229] To generate Sema6A-knockout mice, the transmembrane domain encoding CD4-galactosidase-neomycin phosphotransferase (TM--geo) separated by an internal ribosome entry site (IRES) and human The cassette for placental alkaline phosphatase (PLAP) was inserted into intron 17 of Sema6A as described in Leighton et al., Nature, 410:174-179. The remaining N-terminal portion of the Sema6A protein up to amino acid 623 (thus lacking the transmembrane and cytoplasmic domains) is fused to -galactosidase and retained in the endoplasmic reticulum.

[0230] To analyze the delay in myelination, the nodes of Ranvier in Sema6A-deficient mice were studied. The junction of Ranvier expresses a variety of proteins whose expression and function have been demonstrated to be characteristic of the junction. Antibodies raised against proteins involved in the formation of Ranvier junctions, such as paranodin, were used to detect protein ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention provides methods of treating diseases, disorsers or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a Sema6A polypeptide.

Description

technical field [0001] The present invention relates to neurobiology, neurology and pharmacology. More specifically, it relates to methods of treating diseases involving central nervous system myelination by administering Semaphorin 6A ("Sema6A") polypeptides. Background technique [0002] Many neurological diseases are associated with demyelination and dysmyelination, including multiple sclerosis (MS), progressive multifocal leukoencephalopathy (PML), encephalomyelitis (EPL), central pontine myelolysis, CPM), Wallerian degeneration, and some genetic diseases such as adrenoleukodystrophy, Alexander disease and Pelizaeus Merzbacher disease (PMZ). Of these diseases, MS is the most widespread, affecting approximately 2.5 million people worldwide. [0003] MS usually begins with a relapsing-remitting pattern involving nerves, which then progresses to a chronic phase as nerve damage worsens. MS is associated with destruction of myelin sheaths, oligodendrocytes, and axons local...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K48/00A61P25/00A61K35/12C12N5/079C12N5/0793
CPCC12N5/0619C12N2501/998A61K38/1709C12N2502/08A01K2227/105C12N5/0622C12N2510/00A01K2217/072A01K67/0276A61K35/12C07K14/705A61P21/02A61P25/00A61P25/04A61P25/14A61P25/16A61P25/28A61P27/02A61P3/02A61P43/00A61P9/10C12N5/00A61K38/17A61K48/00C07K14/47
Inventor 阿莱恩·舍多塔尔沙·米弗雷德里克·伯纳德
Owner BIOGEN MA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap